Key facts

Fact sheet

Contacts

Latest aide memoire

Sustainability

Sustainability

Making Science Accessible

As we look ahead to pursuing our science-led strategy in the years up to 2025, we have identified three priority areas. We want to ensure that we broaden access to healthcare, minimise our environmental footprint, and ensure ethics and transparency underpin everything we do.

Emerging markets

Expansion, Innovation and Partnership

Emerging Markets are key to the ongoing pipeline- and sales-driven transformation of AstraZeneca. Over the past years, our global sales base has changed from having most of sales coming from what we now call ‘Other’ medicines to our current setup where our business is focused on three main therapy areas: Oncology, New Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. In these therapy areas, Emerging Markets now outperform the rest of the world.

This data might not be the latest available

Share calculator
Share chart

Upcoming events

Virtual conference, Bank of America, Health Care Conference in Napa [management]

Downloads Available

Virtual conference, J.P. Morgan, European Healthcare Conference [management]

Downloads Available

View all events

Annual Reports

 

2020

Download our Annual Report and Form 20-F Information 2020

PDF 12,602KB

View online summary

2019

Download our Annual Report and Form 20-F Information 2019

PDF 11,262KB

View online summary

2018

Download our Annual Report and Form 20-F Information 2018

PDF 7,964KB

View online summary

2017

Download our Annual Report and Form 20-F Information 2017

PDF 14,751KB

View online summary

2016

Download the AstraZeneca Annual Report and Form 20-F Information 2016

PDF 18,551KB

View online summary

2015

Download the full Annual Report and Form 20-F Information 2015

PDF 10,487KB

View online summary

2006-2014

AstraZeneca Annual Report – English 2014

PDF 5,660KB

AstraZeneca Annual Report – Swedish 2014

PDF 4,097KB

AstraZeneca PLC Long Term Incentive Plans for Executive Directors 2014

PDF 102KB

AstraZeneca Annual Report – English 2013

PDF 4,810KB

AstraZeneca Annual Report – Swedish 2013

PDF 4,031KB

AstraZeneca Annual Report and Form 20-F Information 2012 - English

PDF 11,072KB

AstraZeneca Annual Report and Form 20-F Information 2012 – Swedish

PDF 3,986KB

AstraZeneca Annual Report and Form 20-F Information 2011 – English

PDF 13,076KB

AstraZeneca Annual Report and Form 20-F Information 2011 – Swedish

PDF 6,024KB

AstraZeneca Annual Report and Form 20-F Information 2010 – English

PDF 4,864KB

AstraZeneca Annual Report and Form 20-F Information 2010– Swedish

PDF 8,237KB

AstraZeneca Annual Report and Form 20-F Information 2009 – English

PDF 5,824KB

AstraZeneca Annual Report and Form 20-F Information 2009 – Swedish

PDF 3,420KB

AstraZeneca Annual Report and Form 20-F Information 2008 – English

PDF 7,122KB

AstraZeneca Annual Report and Form 20-F Information 2008 – Swedish

PDF 1,878KB

AstraZeneca Annual Report and Form 20-F Information 2007 – English

PDF 3,561KB

AstraZeneca Annual Report and Form 20-F Information 2007 – Swedish

PDF 5,115KB

AstraZeneca Annual Report and Form 20-F Information 2006 – English

PDF 1,740KB

AstraZeneca Annual Report and Form 20-F Information 2006 – Swedish

PDF 1,927KB

Annual reports archive

Investor enquiries

Main Contacts

Thomas Kudsk Larsen

+44 203 749 5712

Nick Stone

Oncology

+44 203 749 5716

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

Christer Gruvris

BioPharmaceuticals (Cardiovascular, Renal & Metabolism), Finance

+44 203 749 5711

Josie Afolabi

BioPharmaceuticals (Respiratory & Immunology)

+44 203 749 5631

Tom Waldron

Other medicines, COVID-19

+44 7385 033 717

Lauren Swales

+447789595458

US general enquiries

+1 301 398 3251

  • Shareholder information

    Please find relevant shareholder information and shareholder tools on this page

    View information

  • Shareholder FAQs

    Answers to frequently asked shareholder questions

    View FAQs

  • Governance

    We apply the principles of good corporate governance in the UK Corporate Governance Code and related guidance

    Go to page